- AstraZeneca to Buy Alexion for $39 Billion in Cash and Stock Bloomberg
- AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development Business Wire
- AstraZeneca to acquire Boston biotech Alexion, accelerating the company’s strategic and financial development The Boston Globe
- AstraZeneca Agrees to Buy Alexion for $39 Billion The Wall Street Journal
- AstraZeneca to buy Alexion in $39bn immunology deal Financial Times
- View Full Coverage on Google News
Top stories – Google News
